Nichi-Iko Pharmaceutical Co., Ltd.
Quick facts
Phase 3 pipeline
- NI-071 · Neurology
NI-071 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Nichi-Iko Pharmaceutical Co., Ltd. portfolio CI brief
- Nichi-Iko Pharmaceutical Co., Ltd. pipeline updates RSS
Frequently asked questions about Nichi-Iko Pharmaceutical Co., Ltd.
What is Nichi-Iko Pharmaceutical Co., Ltd.'s pipeline?
Nichi-Iko Pharmaceutical Co., Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include NI-071.
Related
- Sector hub: All tracked pharma companies